COVID-2019 vaccine - OSE Immunotherapeutics
Alternative Names: CoVepiT; CoVepiT COVID-2019 vaccine; COVID-19 prophylactic vaccine; OSE-13ELatest Information Update: 28 May 2024
At a glance
- Originator OSE Immunotherapeutics
- Class COVID-19 vaccines; Peptide vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 May 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention) in Belgium (SC, Injection)
- 16 Mar 2022 Immunogenicity and adverse events data from a phase I trial in COVID-2019 infections released by OSE Immunotherapeutics
- 30 Nov 2021 Additional Pharmacodynamics data from preclinical trial in COVID-2019 infections released by OSE Immunotherapeutics